huPBMC-Mono Mice

Inquiry

Alfa Cytology's huPBMC-Mono mice are a specialized platform designed for the study of myeloid cell-mediated immune responses, including monocytes, macrophages, and dendritic cells. This model enables researchers to evaluate the role of myeloid cells in tumor microenvironment modulation, cancer vaccine efficacy, and macrophage-targeting therapies. With robust reconstitution of human myeloid lineages, the huPBMC-Mono model provides a physiologically relevant system for advancing immuno-oncology and inflammation research.

Introduction to huPBMC-Mono Mice

The huPBMC-Mono model is established by engrafting healthy donor-derived PBMCs into immunodeficient NCG or NSG mice, with a focus on enhancing the survival and function of human monocytes, macrophages, and dendritic cells. Through optimized conditioning and engraftment protocols, Alfa Cytology achieves consistent and functional reconstitution of key myeloid populations, including CD14⁺ monocytes, CD68⁺ macrophages, and CD11c⁺ dendritic cells. This model supports a stable experimental window of 3–4 weeks, allowing for comprehensive evaluation of myeloid-targeting therapeutics and their impact on the tumor immune microenvironment.

Advantages of huPBMC-Mono Mice

Functional Myeloid Reconstitution

Achieves robust reconstruction of human monocytes, macrophages, and dendritic cells in peripheral blood and lymphoid organs.

Tumor Microenvironment Relevance

Supports the study of myeloid cell infiltration, polarization, and function within the tumor microenvironment.

Broad Therapeutic Compatibility

Compatible with over 400 CDX and 400 PDX models for evaluating myeloid-targeting agents.

Stable & Reproducible System

High engraftment consistency with controlled variation in human myeloid cell populations.

Applications of huPBMC-Mono Mice

Macrophage-Targeting Therapy Evaluation

Efficacy and mechanism studies of agents targeting macrophage checkpoints such as CD47-SIRPα, CSF-1R, and CD40.

Cancer Vaccine & Immunomodulator Research

Assessment of cancer vaccines, TLR agonists, and other immunomodulators that activate dendritic cells and enhance antigen presentation.

Tumor Microenvironment & Myeloid Reprogramming

Investigation of myeloid cell polarization, cytokine signaling, and strategies to reprogram suppressive myeloid populations

Case Study

Case 1: Antigen-Specific T Cell Activation in the huPBMC-Mono Model

Overview

Validate that the huPBMC-Mono model supports human antigen presentation and induces antigen-specific CTL responses following immunization.

Study Information

Humanized Model: huPBMC-Mono mice on NSG strain
Treatment: Mice received three rounds of immunization and PBMC injections.

Results

Successful Immune Cell Engraftment: Human PBMCs were successfully recovered from the spleens of engrafted mice 35 days after the first immunization.
Functional Immune Response: Upon stimulation with specific antigen peptides, a significant activation of human CTLs was observed.
Model Validation: The activated CTL response was significantly different from the control group, confirming the model's capability to present antigen and mount a functional, antigen-specific human T cell response.

Fig.1 Antigen-specific human T-cell responses in a huPBMC-Mono model.

The huPBMC-Mono model is a powerful tool for dissecting the role of myeloid cells in immuno-oncology and inflammation. Alfa Cytology's Hu-Immune™ platform provides end-to-end services—from model establishment and study design to functional analysis—enabling you to gain deeper insights into myeloid-driven immune responses. Contact our scientific team now for customized solutions.

For research use only.

Hu-Immune^TM Platform

Online Inquiry

Name *

Email *

Phone

Services Interested *

Project Description

Please note that we are not a pharmacy or clinic, so we are unable to see patients and do not offer diagnostic and treatment services for individuals.